269 related articles for article (PubMed ID: 28595492)
1. Current mathematical models for cancer drug discovery.
Carrara L; Lavezzi SM; Borella E; De Nicolao G; Magni P; Poggesi I
Expert Opin Drug Discov; 2017 Aug; 12(8):785-799. PubMed ID: 28595492
[TBL] [Abstract][Full Text] [Related]
2. Mathematical modeling of efficacy and safety for anticancer drugs clinical development.
Lavezzi SM; Borella E; Carrara L; De Nicolao G; Magni P; Poggesi I
Expert Opin Drug Discov; 2018 Jan; 13(1):5-21. PubMed ID: 28972401
[TBL] [Abstract][Full Text] [Related]
3. Mathematical modeling in cancer drug discovery.
Wang Z; Deisboeck TS
Drug Discov Today; 2014 Feb; 19(2):145-50. PubMed ID: 23831857
[TBL] [Abstract][Full Text] [Related]
4. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.
Venkatakrishnan K; Friberg LE; Ouellet D; Mettetal JT; Stein A; Trocóniz IF; Bruno R; Mehrotra N; Gobburu J; Mould DR
Clin Pharmacol Ther; 2015 Jan; 97(1):37-54. PubMed ID: 25670382
[TBL] [Abstract][Full Text] [Related]
5. Targeted approaches to childhood cancer: progress in drug discovery and development.
Hirsch S; Marshall LV; Carceller Lechon F; Pearson AD; Moreno L
Expert Opin Drug Discov; 2015 May; 10(5):483-95. PubMed ID: 25840490
[TBL] [Abstract][Full Text] [Related]
6. Mathematical modeling for novel cancer drug discovery and development.
Zhang P; Brusic V
Expert Opin Drug Discov; 2014 Oct; 9(10):1133-50. PubMed ID: 25062617
[TBL] [Abstract][Full Text] [Related]
7. Computational modeling in melanoma for novel drug discovery.
Pennisi M; Russo G; Di Salvatore V; Candido S; Libra M; Pappalardo F
Expert Opin Drug Discov; 2016 Jun; 11(6):609-21. PubMed ID: 27046143
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps.
Block M
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):743-56. PubMed ID: 25940026
[TBL] [Abstract][Full Text] [Related]
9. Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development.
Bernard A; Kimko H; Mital D; Poggesi I
Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1057-69. PubMed ID: 22632710
[TBL] [Abstract][Full Text] [Related]
10. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
[TBL] [Abstract][Full Text] [Related]
11. Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside.
Yamazaki S; Spilker ME; Vicini P
Expert Opin Drug Metab Toxicol; 2016; 12(3):253-65. PubMed ID: 26799750
[TBL] [Abstract][Full Text] [Related]
12. Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I.
Geromichalos GD; Alifieris CE; Geromichalou EG; Trafalis DT
J BUON; 2016; 21(4):764-779. PubMed ID: 27685895
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology.
Garralda E; Dienstmann R; Tabernero J
Am Soc Clin Oncol Educ Book; 2017; 37():210-215. PubMed ID: 28561730
[TBL] [Abstract][Full Text] [Related]
15. A new approach to assess drug sensitivity in cells for novel drug discovery.
Mazzarella L; Curigliano G
Expert Opin Drug Discov; 2018 Apr; 13(4):339-346. PubMed ID: 29415581
[TBL] [Abstract][Full Text] [Related]
16. The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system.
Safavi M; Sabourian R; Abdollahi M
Expert Opin Drug Discov; 2016 Oct; 11(10):939-56. PubMed ID: 27454411
[TBL] [Abstract][Full Text] [Related]
17. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.
Kumalo HM; Bhakat S; Soliman ME
Chem Biol Drug Des; 2015 Nov; 86(5):1131-60. PubMed ID: 25958815
[TBL] [Abstract][Full Text] [Related]
18. Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer.
Fleisher B; Brown AN; Ait-Oudhia S
Pharmacol Res; 2017 Oct; 124():20-33. PubMed ID: 28735000
[TBL] [Abstract][Full Text] [Related]
19. Identification of drug candidates and repurposing opportunities through compound-target interaction networks.
Cichonska A; Rousu J; Aittokallio T
Expert Opin Drug Discov; 2015 Dec; 10(12):1333-45. PubMed ID: 26429153
[TBL] [Abstract][Full Text] [Related]
20. The multicellular tumor spheroid model for high-throughput cancer drug discovery.
LaBarbera DV; Reid BG; Yoo BH
Expert Opin Drug Discov; 2012 Sep; 7(9):819-30. PubMed ID: 22788761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
